Logo image of GRDN

GUARDIAN PHRMCY SERVICES-A (GRDN) Stock Fundamental Analysis

NYSE:GRDN - New York Stock Exchange, Inc. - US40145W1018 - Common Stock - Currency: USD

18.7  -1.1 (-5.56%)

Fundamental Rating

3

Taking everything into account, GRDN scores 3 out of 10 in our fundamental rating. GRDN was compared to 40 industry peers in the Consumer Staples Distribution & Retail industry. GRDN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GRDN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year GRDN has reported negative net income.
Each year in the past 5 years GRDN has been profitable.
Each year in the past 5 years GRDN had a positive operating cash flow.
GRDN Yearly Net Income VS EBIT VS OCF VS FCFGRDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 20M 40M 60M

1.2 Ratios

With a Return On Assets value of -28.18%, GRDN is not doing good in the industry: 87.18% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -76.89%, GRDN is doing worse than 87.18% of the companies in the same industry.
Industry RankSector Rank
ROA -28.18%
ROE -76.89%
ROIC N/A
ROA(3y)9.85%
ROA(5y)9.96%
ROE(3y)78.6%
ROE(5y)72.36%
ROIC(3y)N/A
ROIC(5y)N/A
GRDN Yearly ROA, ROE, ROICGRDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 20 40 60 80

1.3 Margins

In the last couple of years the Profit Margin of GRDN has declined.
GRDN's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 19.92%, GRDN is doing worse than 64.10% of the companies in the same industry.
GRDN's Gross Margin has been stable in the last couple of years.
GRDN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.92%
OM growth 3Y-4.38%
OM growth 5YN/A
PM growth 3Y-5.53%
PM growth 5YN/A
GM growth 3Y-0.1%
GM growth 5YN/A
GRDN Yearly Profit, Operating, Gross MarginsGRDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 5 10 15 20

More info and screens

4

2. Health

2.1 Basic Checks

GRDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
GRDN has about the same amout of shares outstanding than it did 1 year ago.
GRDN has a worse debt/assets ratio than last year.
GRDN Yearly Shares OutstandingGRDN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M
GRDN Yearly Total Debt VS Total AssetsGRDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 8.70 indicates that GRDN is not in any danger for bankruptcy at the moment.
GRDN has a better Altman-Z score (8.70) than 89.74% of its industry peers.
GRDN has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.30, GRDN is doing good in the industry, outperforming 64.10% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Altman-Z 8.7
ROIC/WACCN/A
WACC8.94%
GRDN Yearly LT Debt VS Equity VS FCFGRDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.3 Liquidity

GRDN has a Current Ratio of 1.14. This is a normal value and indicates that GRDN is financially healthy and should not expect problems in meeting its short term obligations.
GRDN's Current ratio of 1.14 is in line compared to the rest of the industry. GRDN outperforms 51.28% of its industry peers.
GRDN has a Quick Ratio of 1.14. This is a bad value and indicates that GRDN is not financially healthy enough and could expect problems in meeting its short term obligations.
GRDN has a Quick ratio of 0.85. This is in the better half of the industry: GRDN outperforms 69.23% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 0.85
GRDN Yearly Current Assets VS Current LiabilitesGRDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

GRDN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.33%.
Measured over the past 5 years, GRDN shows a small growth in Earnings Per Share. The EPS has been growing by 5.90% on average per year.
Looking at the last year, GRDN shows a quite strong growth in Revenue. The Revenue has grown by 15.10% in the last year.
The Revenue has been growing by 12.44% on average over the past years. This is quite good.
EPS 1Y (TTM)-33.33%
EPS 3Y5.9%
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)15.1%
Revenue growth 3Y12.44%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GRDN will show a very strong growth in Earnings Per Share. The EPS will grow by 31.65% on average per year.
GRDN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.80% yearly.
EPS Next Y-423.45%
EPS Next 2Y40.94%
EPS Next 3Y31.65%
EPS Next 5YN/A
Revenue Next Year18.05%
Revenue Next 2Y13.72%
Revenue Next 3Y9.8%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GRDN Yearly Revenue VS EstimatesGRDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B
GRDN Yearly EPS VS EstimatesGRDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GRDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 24.77, which indicates a rather expensive current valuation of GRDN.
GRDN's Price/Forward Earnings ratio is in line with the industry average.
GRDN is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.65, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 24.77
GRDN Price Earnings VS Forward Price EarningsGRDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRDN Per share dataGRDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

A more expensive valuation may be justified as GRDN's earnings are expected to grow with 31.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.94%
EPS Next 3Y31.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GRDN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GUARDIAN PHRMCY SERVICES-A

NYSE:GRDN (2/26/2025, 3:39:02 PM)

18.7

-1.1 (-5.56%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners104.31%
Inst Owner Change-83.49%
Ins Owners0.96%
Ins Owner Change100%
Market Cap1.18B
Analysts84.44
Price Target24.82 (32.73%)
Short Float %8.88%
Short Ratio5.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.39%
PT rev (3m)1.39%
EPS NQ rev (1m)5.88%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.41%
EPS NY rev (3m)-255.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 24.77
P/S 0.61
P/FCF N/A
P/OCF N/A
P/B 9.28
P/tB 26.9
EV/EBITDA N/A
EPS(TTM)-1.62
EYN/A
EPS(NY)0.75
Fwd EY4.04%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS30.59
BVpS2.02
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.18%
ROE -76.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.92%
FCFM N/A
ROA(3y)9.85%
ROA(5y)9.96%
ROE(3y)78.6%
ROE(5y)72.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)30.36%
ROCE(5y)29.87%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-4.38%
OM growth 5YN/A
PM growth 3Y-5.53%
PM growth 5YN/A
GM growth 3Y-0.1%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover5.56
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 0.85
Altman-Z 8.7
F-ScoreN/A
WACC8.94%
ROIC/WACCN/A
Cap/Depr(3y)79.08%
Cap/Depr(5y)75.45%
Cap/Sales(3y)1.47%
Cap/Sales(5y)1.52%
Profit Quality(3y)208.9%
Profit Quality(5y)208.02%
High Growth Momentum
Growth
EPS 1Y (TTM)-33.33%
EPS 3Y5.9%
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-423.45%
EPS Next 2Y40.94%
EPS Next 3Y31.65%
EPS Next 5YN/A
Revenue 1Y (TTM)15.1%
Revenue growth 3Y12.44%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year18.05%
Revenue Next 2Y13.72%
Revenue Next 3Y9.8%
Revenue Next 5YN/A
EBIT growth 1Y-21.24%
EBIT growth 3Y7.52%
EBIT growth 5YN/A
EBIT Next Year116.42%
EBIT Next 3Y37.1%
EBIT Next 5YN/A
FCF growth 1Y77.2%
FCF growth 3Y8.32%
FCF growth 5YN/A
OCF growth 1Y45.95%
OCF growth 3Y10.41%
OCF growth 5YN/A